Carnmt1 Antibody

What is CARNMT1 and what are its principal biological functions?

CARNMT1 (also known as UPF0586 or C9orf41) is a seven-β-strand (7BS) methyltransferase that functions as a histidine N1-position-specific methyltransferase. Originally identified as a carnosine methyltransferase from rat skeletal muscles, CARNMT1 catalyzes the S-adenosyl methionine (SAM/AdoMet)-dependent methylation of histidine on dipeptide carnosine (βAla-His) . Recent research has revealed that CARNMT1's functions extend far beyond carnosine methylation, playing crucial roles in RNA metabolism by methylating C3H zinc finger (ZF)-type RNA-binding proteins involved in mRNA degradation and alternative splicing .

The amino acid sequence of CARNMT1 is highly conserved from yeast to mammals, though distinct from other 7BS methyltransferases or SET domain methyltransferases, suggesting its evolutionary importance . CARNMT1 deficiency in mouse models results in embryonic lethality, underscoring its essential role in embryonic development .

What are the primary substrates of CARNMT1?

CARNMT1 exhibits a dual substrate specificity, methylating both small peptides and specific proteins:

Table 1: Known Substrates of CARNMT1

Research has identified 52 histidine sites across 20 proteins that undergo CARNMT1-mediated methylation . Most notably, CARNMT1 preferentially methylates the histidine residues within the consensus Cx(F/Y)xH motif, which corresponds to the C3H zinc finger motif found in RNA-binding proteins . For example, endogenous U2AF1 (a splicing factor) is almost completely (>99%) methylated at the H37 position in its first C3H ZF motif in wild-type cells, while this methylation is virtually absent (<0.1%) in CARNMT1 knockout cells .

How does CARNMT1 deficiency affect cellular processes?

CARNMT1 deficiency has profound effects on multiple cellular processes, particularly those involving RNA metabolism:

• Embryonic development: CARNMT1-deficient and catalytically inactive mutant mice show embryonic lethality, indicating that CARNMT1's enzymatic activity is essential for proper embryonic development .

• RNA degradation: The function of C3H ZF proteins like Roquin and tristetraprolin (TTP), which mediate RNA degradation, is affected by CARNMT1 deficiency and loss of its enzymatic activity .

• Alternative splicing: Recognition of the 3′ splice site by the CARNMT1 target C3H ZF protein U2AF1 is perturbed in CARNMT1-deficient cells, affecting pre-mRNA alternative splicing patterns .

• Histidine methylation levels: CARNMT1 knockout cells show approximately 50% reduction in N1-methylhistidine (1MH) levels, while double knockout of CARNMT1 and METTL9 (another histidine methyltransferase) results in undetectable (<0.003%) levels of 1MH .

What is the consensus methylation motif for CARNMT1 and how was it determined?

The consensus methylation motif for CARNMT1 has been identified as Cx(F/Y)xH, which corresponds to the C3H zinc finger motif . This discovery was made through systematic analysis of CARNMT1 substrates using multiple complementary approaches:

• In vitro methylation assays: Recombinant GST-tagged full-length mouse CARNMT1 was tested against various peptides with known histidine methylation sites. CARNMT1 methylated histidine residues in specific sequence contexts, showing preference for certain motifs .

• Mass spectrometry analysis: LC-MS/MS analysis of proteins methylated by CARNMT1 revealed that histidine sites with >50% methylation shared the Cx(F/Y)xH consensus sequence .

• Substrate validation: Analysis of individual proteins like MKRN2 showed higher methylation levels at histidine residues within C3H ZF motifs (H26, H55, H189, and H347) compared to histidine in other contexts, such as the C3HC4-type zinc finger RING domain (H264) .

This precise motif recognition explains CARNMT1's specificity for C3H ZF-type RNA-binding proteins and provides a molecular basis for identifying potential new substrates in research contexts.

How do CARNMT1 and METTL9 cooperate in regulating protein histidine methylation?

CARNMT1 and METTL9 represent the two major histidine methyltransferases responsible for N1-position-specific histidine methylation in mammalian cells. Their relationship was elucidated through sophisticated knockout studies:

Table 2: Contribution of CARNMT1 and METTL9 to Cellular Histidine Methylation

These findings reveal several important insights about the cooperation between these enzymes:

• Both CARNMT1 and METTL9 contribute approximately equally to the total N1-position-specific histidine methylation in cells, each accounting for about 50% of cellular N1-methylhistidine levels .

• The complete loss of N1-methylhistidine in double knockout cells indicates that these two enzymes are together responsible for virtually all N1-position-specific histidine methylation in the cell types studied .

• The enzymes have distinct substrate preferences: CARNMT1 preferentially targets the Cx(F/Y)xH motif in C3H ZF proteins and contributes to anserine production, while METTL9 has different target specificity and does not significantly affect anserine levels .

• Neither enzyme affects N3-position histidine methylation (3MH/τMH), indicating position-specific enzymatic activity .

This relationship demonstrates how cells employ multiple specialized methyltransferases to regulate different subsets of the proteome through specific post-translational modifications.

What techniques can be used to identify novel CARNMT1 substrates?

The identification of novel CARNMT1 substrates requires sophisticated methodological approaches that combine chemical biology, proteomics, and molecular biology techniques:

• ProSeAM-based substrate identification: An alkyne-substituted SAM analog (ProSeAM) can be used for in vitro propargylation of histidine residues in potential substrate proteins. This approach was successfully employed to identify 22 proteins as CARNMT1 substrate candidates .

The workflow involves:

• Culturing CARNMT1 knockout cells in light or heavy isotope-labeled medium

• Incubating cell lysates with ProSeAM with or without recombinant CARNMT1

• Adding a biotin tag via the CuAAC reaction (click chemistry)

• Purifying biotinylated proteins with streptavidin beads

• Analyzing the proteins by LC-MS/MS

• Substrate validation through rescue experiments: CARNMT1 knockout cells can be rescued with wild-type or catalytically dead mutant CARNMT1 to confirm substrate specificity. For example, FLAG-tagged MKRN2 was shown to be methylated at specific histidine residues in wild-type and rescue cells but not in knockout or catalytically dead mutant cells .

• Amino acid analysis: To confirm the position specificity of methylation (N1 vs. N3), amino acid analysis of purified substrate proteins is essential. This technique confirmed that CARNMT1 introduces a methyl group specifically into the N1 position of histidine .

• Immunoprecipitation-mass spectrometry: Endogenous proteins can be immunoprecipitated from wild-type and CARNMT1 knockout cells and analyzed by LC-MS/MS to identify methylation sites. This approach confirmed that endogenous U2AF1 is heavily methylated at H37 in wild-type cells but not in CARNMT1 knockout cells .

What are the critical considerations when selecting a CARNMT1 antibody for research applications?

When selecting a CARNMT1 antibody for research applications, consider the following critical factors:

• Epitope specificity: Determine whether the antibody recognizes the N-terminal, C-terminal, or internal epitopes of CARNMT1. This is particularly important when studying truncated variants or splice isoforms. The search results indicate that CARNMT1 can appear as a wide band with an estimated molecular mass of 55-59 kDa, corresponding to several predicted protein variants with 502-550 amino acids .

• Cross-reactivity testing: Validate that the antibody does not cross-react with related methyltransferases like METTL9. This is essential given that both enzymes contribute to N1-histidine methylation in cells .

• Validation in knockout models: The antibody should be tested in both wild-type and CARNMT1 knockout samples to confirm specificity. In the referenced study, CARNMT1 expression was detectable by western blotting in wild-type and heterozygous but not in knockout mice, confirming antibody specificity .

• Application compatibility: Ensure the antibody is validated for your specific application (western blotting, immunoprecipitation, immunofluorescence, etc.). Different applications may require different antibody characteristics.

What controls are essential when using CARNMT1 antibodies in experimental settings?

Proper controls are crucial for generating reliable data with CARNMT1 antibodies:

Table 3: Essential Controls for CARNMT1 Antibody Experiments

The implementation of these controls is exemplified in the research where CARNMT1 knockout cells were rescued with either wild-type CARNMT1 or a catalytically dead mutant in which glycine residues in the catalytic domain (G199/201) were substituted with arginine (G199/201R) . This approach effectively distinguished between the presence of the protein and its enzymatic activity.

What are effective protocols for detecting CARNMT1-mediated histidine methylation?

Detecting CARNMT1-mediated histidine methylation requires specialized techniques:

• Multiple Reaction Monitoring (MRM) LC-MS/MS: This highly sensitive approach was used to quantify total protein histidine methylation levels in wild-type and knockout cells. The technique revealed that CARNMT1 knockout cells showed ~50% reduction in N1-methylhistidine levels .

• Amino acid analysis of methylated peptides: This technique can distinguish between N1-position-specific and N3-position-specific histidine methylation. For example, CARNMT1-methylated peptides showed a single peak corresponding to the 1MH standard (t = 28.0 min), confirming N1-position-specific methylation .

• In vitro methylation assays: Recombinant CARNMT1 can be used to methylate potential substrate peptides or proteins in vitro, followed by detection of methylation through various methods:

  • Radiolabeled SAM incorporation

  • ProSeAM labeling followed by click chemistry

  • Mass spectrometry analysis

• Immunoprecipitation-mass spectrometry: This approach can identify specific methylation sites in endogenous proteins. For example, endogenous U2AF1 was immunoprecipitated with an anti-U2AF1 antibody from wild-type or CARNMT1 knockout cells, and methylation at H37 was determined via LC-MS/MS analysis .

How can researchers distinguish between direct and indirect effects of CARNMT1 inhibition?

Distinguishing between direct and indirect effects of CARNMT1 inhibition is crucial for accurately interpreting experimental results:

• Rescue experiments with wild-type vs. catalytically dead mutants: By reintroducing either wild-type CARNMT1 or a catalytically inactive variant (e.g., G199/201R mutant) into CARNMT1 knockout cells, researchers can determine which phenotypes depend specifically on CARNMT1's enzymatic activity versus its physical presence .

• Substrate-specific mutants: Generating point mutations in the histidine residues of specific CARNMT1 substrates (e.g., H37 in U2AF1) can help determine whether observed phenotypes are due to methylation of that particular substrate.

• In vitro competition assays: Studies showed that carnosine inhibited protein methylation at ~3 mM (IC50 = 3.2 mM ± 1.2 mM), whereas anserine showed no inhibitory effect up to 30 mM. This suggests that protein substrates and carnosine compete for CARNMT1, providing a method to modulate CARNMT1 activity selectively .

• Comparative transcriptomics: RNA sequencing revealed that CARNMT1 knockout alters the expression of genes involved in drug metabolism and other pathways. For example, β-ureidopropionase 1 (UPB1) showed a twofold increase in CARNMT1 knockout mice, suggesting a compensatory mechanism for maintaining β-alanine synthesis .

How should experiments be designed to study CARNMT1's role in RNA metabolism?

CARNMT1 plays critical roles in RNA metabolism through its methylation of C3H ZF-type RNA-binding proteins. Effective experimental design should account for multiple aspects of RNA processing:

• Alternative splicing analysis: Since CARNMT1 affects the function of splicing factors like U2AF1, researchers should employ RNA-seq with specific analysis pipelines designed to detect differential splicing events between wild-type and CARNMT1-deficient cells .

• mRNA degradation assays: CARNMT1 targets RNA-binding proteins involved in mRNA degradation, such as Roquin and tristetraprolin (TTP). Pulse-chase experiments with labeled RNA can reveal differences in mRNA stability in the presence or absence of CARNMT1 .

• Protein-RNA interaction studies: RNA immunoprecipitation (RIP) or cross-linking immunoprecipitation (CLIP) can be used to determine how CARNMT1-mediated methylation affects the RNA-binding properties of its substrate proteins.

• Developmental timeline analysis: Given CARNMT1's essential role in embryonic development, time-course studies using conditional knockout models can help determine critical developmental windows during which CARNMT1 activity is required.

When designing these experiments, researchers should include appropriate controls:

• Wild-type vs. CARNMT1 knockout

• CARNMT1 knockout rescued with wild-type CARNMT1

• CARNMT1 knockout rescued with catalytically inactive CARNMT1

• Tissue-specific or inducible knockouts to bypass embryonic lethality

What are the advantages and limitations of different model systems for studying CARNMT1 function?

Different model systems offer unique advantages and limitations for CARNMT1 research:

Table 4: Comparison of Model Systems for CARNMT1 Research

The research demonstrated that complete CARNMT1 knockout in mice results in embryonic lethality, necessitating alternative approaches for studying its function in adult tissues . Cell line models like HEK293T and HAP1 have proven valuable for biochemical characterization, with CARNMT1 knockout cells showing approximately 50% reduction in N1-methylhistidine levels .

How can researchers quantify changes in CARNMT1 expression and activity across different experimental conditions?

Accurate quantification of CARNMT1 expression and activity is essential for understanding its regulation and function:

• mRNA expression analysis:

  • qRT-PCR targeting specific exons (particularly important when studying splice variants)

  • RNA-seq for comprehensive transcriptomic analysis

  • Exon-specific primers to detect alternative splicing events

• Protein expression analysis:

  • Western blotting with specific antibodies

  • Immunohistochemistry for tissue localization

  • SILAC (Stable Isotope Labeling with Amino acids in Cell culture) for quantitative proteomics

• Enzymatic activity assays:

  • In vitro methylation assays using recombinant CARNMT1 and known substrates

  • Measurement of N1-methylhistidine levels by MRM LC-MS/MS

  • Quantification of anserine/carnosine ratios by MRM LC-MS/MS

• Substrate methylation status:

  • Immunoprecipitation followed by LC-MS/MS analysis of specific methylation sites

  • Site-specific antibodies against methylated histidine residues in key substrates

When applying these methods, researchers should consider the dual substrate specificity of CARNMT1, targeting both small peptides like carnosine and proteins containing the Cx(F/Y)xH motif . Changes in anserine levels can serve as a biomarker for CARNMT1 activity, as demonstrated by the reduced anserine levels in CARNMT1 knockout cells (~6% relative to carnosine) compared to wild-type cells (~15% relative to carnosine) .

What are common challenges when using CARNMT1 antibodies and how can they be addressed?

Researchers working with CARNMT1 antibodies may encounter several challenges:

• Multiple protein bands: CARNMT1 can appear as a wide band (55-59 kDa) corresponding to several predicted protein variants with 502-550 amino acids . This variability can complicate interpretation of western blot results.

  Solution: Use CARNMT1 knockout samples as negative controls to confirm band specificity. Consider longer gel running times or gradient gels for better separation of closely migrating variants.

• Low signal intensity: CARNMT1 expression may be tissue-specific and relatively low in some contexts.

  Solution: Optimize protein extraction methods, increase antibody concentration or incubation time, and use enhanced chemiluminescence detection systems. Consider concentrating the protein by immunoprecipitation before western blotting.

• Cross-reactivity with related methyltransferases: CARNMT1 belongs to the seven-β-strand (7BS) methyltransferase family, which may share structural similarities with other family members.

  Solution: Validate antibody specificity using knockout controls and competitive binding assays with purified recombinant proteins.

• Variable expression across tissues: CARNMT1 expression patterns may differ significantly between tissues and developmental stages.

  Solution: Normalize expression to appropriate housekeeping genes or proteins for the specific tissue being studied. Consider using tissue-specific positive controls known to express CARNMT1.

How can inconsistent results with CARNMT1 antibodies be systematically investigated?

When facing inconsistent results with CARNMT1 antibodies, a systematic troubleshooting approach is essential:

• Antibody validation:

  • Test multiple antibodies targeting different epitopes of CARNMT1

  • Verify antibody specificity using knockout controls

  • Check antibody lot-to-lot variability

  • Confirm antibody storage conditions and expiration dates

• Sample preparation optimization:

  • Test different lysis buffers to ensure efficient protein extraction

  • Evaluate the impact of protease and phosphatase inhibitors

  • Compare fresh vs. frozen samples

  • Assess the effects of denaturation conditions (temperature, reducing agents)

• Technical variables:

  • Standardize protein quantification methods

  • Optimize blocking conditions to reduce background

  • Test different membrane types (PVDF vs. nitrocellulose)

  • Evaluate primary and secondary antibody concentrations and incubation times

• Experimental design considerations:

  • Include appropriate positive and negative controls in each experiment

  • Use internal loading controls

  • Implement biological and technical replicates

  • Blind sample identification during analysis to prevent bias

By systematically addressing these variables, researchers can identify and resolve sources of inconsistency in CARNMT1 antibody applications.